TapImmune, Inc. (OTCQB: TPIV) is an immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease. The company’s vaccine compositions, peptide or nucleic acid-based, comprise one or multiple naturally processed epitopes (NPEs) that are designed to comprehensively stimulate a patients’ killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. TapImmune’s vaccine compositions may be used as stand-alone medications or in combination with current treatment modalities. For more information, visit the company’s website at www.tapimmune.com